Considering adjuvant therapy for stage II melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Considering adjuvant therapy for stage II melanoma

Published:2019-12-23 Issue:6 Volume:126 Page:1166-1174
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Poklepovic Andrew S.¹²^ORCID,Luke Jason J.³⁴^ORCID

Affiliation:

1. Department of Medicine Virginia Commonwealth University Richmond Virginia

2. Massey Cancer Center Virginia Commonwealth University Richmond Virginia

3. Department of Medicine University of Pittsburgh Medical Center Pittsburgh Pennsylvania

4. Hillman Cancer Center University of Pittsburgh Medical Center Pittsburgh Pennsylvania

Funder

U.S. Department of Defense

National Cancer Institute

Melanoma Research Alliance

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32585

Reference47 articles.

1. Cancer statistics, 2015

2. Cancer statistics, 2018

3. Indoor Tanning — Science, Behavior, and Policy

4. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of tubulin β-3 and 5 hydroxy-methyl cytosine as diagnostic and prognostic markers in malignant melanoma;Annals of Diagnostic Pathology;2024-10

2. Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma;Melanoma Research;2024-05-27

3. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial;Journal for ImmunoTherapy of Cancer;2024-03

4. Adjuvant therapy for stage IIB + IIC melanoma;Journal of Surgical Oncology;2023-11-30

5. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial;Nature Medicine;2023-10-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3